Next 10 |
home / stock / esalf / esalf news
2024-07-02 13:54:29 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Eli Lilly, Novo under pressure as Biden urges lower...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...
2024-07-01 15:03:10 ET Read the full article on Seeking Alpha For further details see: Eisai receives rights to antibody drug conjugate after Bristol ends collaboration
2024-06-28 06:17:57 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai’s ( OTCPK:ESALF ) ( OTCPK:ESAIY ) breakthrough Alzheimer's therapy, Leqembi (lecanemab), is now available in China, the companies announced late Thursday.... Read the full article ...
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...
2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...
2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...
2024-06-10 12:09:47 ET More on Biogen, Eisai , etc. Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript Eisai Co Ltd. (ESALF) Q4 2024 Earnings Call Transcript Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Lilly's donanemab, remternetug set to d...
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., June 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today tha...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...